Leeds Assessment of Neuropathic Symptoms and Signs (LANSS): Difference between revisions
(Created initial content) |
No edit summary |
||
| Line 7: | Line 7: | ||
</div> | </div> | ||
== Objective == | == Objective == | ||
The LANSS was developed to provide a simple clinical tool that can be used to | The LANSS was developed to provide a simple clinical tool that can be used to identify pain of predominantly neuropathic origin, thus distinguishing between neuropathic pain and nociceptive pain<ref name=":0">Bennett M. [https://www.researchgate.net/publication/12013304_The_LANSS_pain_scale_The_Leeds_Assessment_of_Neuropathic_Symptoms_and_Signs The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs.] Pain. 2001 May 1;92(1-2):147-57.</ref>. By identifying neuropathic pain mechanisms, more individualised treatment can follow. The LANSS was developed in 2001, and a self-report version, the S-LANSS was developed in 2005<ref name=":1">Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. The Journal of Pain. 2005 Mar 1;6(3):149-58.</ref>. | ||
== Intended Population == | == Intended Population == | ||
The LANSS can be used in any patient presenting with chronic pain. Conditions that often have a neuropathic component include: | |||
* Phantom limb pain | |||
* Cancer | |||
* Diabetic neuropathies | |||
* Peripheral neuropathies | |||
* Stroke | |||
* Spinal cord injury | |||
* Complex regional pain syndrome | |||
* Chronic low back pain | |||
== Method of Use == | == Method of Use == | ||
'''LANSS:''' Contains 5 symptoms items and 2 clinical examination items<ref name=":0" /> | |||
'''S-LANSS:''' A 7-item self-reported questionnaire without a clinical assessment component. It's accuracy is slightly improved when used in an interview format (rather than self-completed)<ref name=":1" />. | |||
== Reference == | == Reference == | ||
== Evidence == | == Evidence == | ||
It is important to consider clinical judgement and clinical findings in combination with screening tools - screening tools fail to identify about 10-20% of patients with neuropathic pain<ref name=":2">Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, Scholz J, Tölle TR, Wittchen HU, Jensen TS. Using screening tools to identify neuropathic pain. Pain. 2007 Feb 1;127(3):199-203.</ref> | |||
=== LANSS === | |||
The LANSS has been tested and validated in several settings/conditions (including cancer pain and chronic low back pain)<ref name=":2" /> | |||
* '''Sensitivity:''' Ranges from 82-91%<ref name=":2" /> | |||
* '''Specificity:''' Ranges from 80-94%<ref name=":2" /> | |||
=== | === S-LANSS === | ||
== | * Internal consistency and convergent validity was demonstrated with its development<ref name=":1" /> | ||
* '''Sensitivity:''' Ranges from 52-78%<ref name=":1" /><ref>Weingarten TN, Watson JC, Hooten WM, Wollan PC, Melton III LJ, Locketz AJ, Wong GY, Yawn BP. Validation of the S-LANSS in the community setting. Pain. 2007 Nov 1;132(1-2):189-94.</ref> | |||
=== | === Additional Languages === | ||
* '''Turkish:''' The Turkish translation of the S-LANSS has been validated for use<ref>Koc R, Erdemoglu AK. Validity and reliability of the Turkish Self-administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire. Pain Medicine. 2010 Jul 1;11(7):1107-14.</ref> | |||
== Links == | === Links === | ||
'''[https://bpac.org.nz/BPJ/2016/May/docs/s-lanss.pdf S-LANSS Pain Score]''' | '''[https://bpac.org.nz/BPJ/2016/May/docs/s-lanss.pdf S-LANSS Pain Score]''' | ||
Revision as of 09:56, 26 July 2023
This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (26/07/2023)
Original Editor - Melissa Coetsee
Top Contributors - Melissa Coetsee
Objective[edit | edit source]
The LANSS was developed to provide a simple clinical tool that can be used to identify pain of predominantly neuropathic origin, thus distinguishing between neuropathic pain and nociceptive pain[1]. By identifying neuropathic pain mechanisms, more individualised treatment can follow. The LANSS was developed in 2001, and a self-report version, the S-LANSS was developed in 2005[2].
Intended Population[edit | edit source]
The LANSS can be used in any patient presenting with chronic pain. Conditions that often have a neuropathic component include:
- Phantom limb pain
- Cancer
- Diabetic neuropathies
- Peripheral neuropathies
- Stroke
- Spinal cord injury
- Complex regional pain syndrome
- Chronic low back pain
Method of Use[edit | edit source]
LANSS: Contains 5 symptoms items and 2 clinical examination items[1]
S-LANSS: A 7-item self-reported questionnaire without a clinical assessment component. It's accuracy is slightly improved when used in an interview format (rather than self-completed)[2].
Reference[edit | edit source]
Evidence[edit | edit source]
It is important to consider clinical judgement and clinical findings in combination with screening tools - screening tools fail to identify about 10-20% of patients with neuropathic pain[3]
LANSS[edit | edit source]
The LANSS has been tested and validated in several settings/conditions (including cancer pain and chronic low back pain)[3]
S-LANSS[edit | edit source]
- Internal consistency and convergent validity was demonstrated with its development[2]
- Sensitivity: Ranges from 52-78%[2][4]
Additional Languages[edit | edit source]
- Turkish: The Turkish translation of the S-LANSS has been validated for use[5]
Links[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001 May 1;92(1-2):147-57.
- ↑ 2.0 2.1 2.2 2.3 Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. The Journal of Pain. 2005 Mar 1;6(3):149-58.
- ↑ 3.0 3.1 3.2 3.3 Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, Scholz J, Tölle TR, Wittchen HU, Jensen TS. Using screening tools to identify neuropathic pain. Pain. 2007 Feb 1;127(3):199-203.
- ↑ Weingarten TN, Watson JC, Hooten WM, Wollan PC, Melton III LJ, Locketz AJ, Wong GY, Yawn BP. Validation of the S-LANSS in the community setting. Pain. 2007 Nov 1;132(1-2):189-94.
- ↑ Koc R, Erdemoglu AK. Validity and reliability of the Turkish Self-administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire. Pain Medicine. 2010 Jul 1;11(7):1107-14.
